Nonsteroidal anti-inflammatory drugs and prostatic diseases

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ishiguro, Hitoshi ^a,b   Kawahara, Takashi ^b  

^a KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; FINASTERIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN D; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROSTAGLANDIN G2; PROSTAGLANDIN H; ROFECOXIB; VASCULOTROPIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; HUMAN; MALE; NONHUMAN; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; REVIEW; ANIMAL; INFLAMMATION; METABOLISM; PROSTATIC DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATION; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROSTATIC DISEASES;

EID: 84901815775     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/436123     Document Type: Review

References (69)

1. Schrecengost R., Knudsen K. E., Molecular pathogenesis and progression of prostate cancer. Seminars in Oncology 2013 40 3 244 258 10.1053/j.seminoncol. 2013.04.001
2. Penna G., Mondaini N., Amuchastegui S., Innocenti S. D., Carini M., Giubilei G., Fibbi B., Colli E., Maggi M., Adorini L., Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European Urology 2007 51 2 524 533 2-s2.0-33845570300 10.1016/j.eururo.2006.07.016 (Pubitemid 44937795)
3. Macoska J. A., Chemokines and BPH/LUTS. Differentiation 2011 82 4-5 253 260 2-s2.0-80052963569 10.1016/j.diff.2011.04.003
4. Cai T., Mazzoli S., Meacci F., Boddi V., Mondaini N., Malossini G., Bartoletti R., Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. The Journal of Microbiology 2011 49 3 448 454 2-s2.0-79959724708 10.1007/s12275-011-0391-z
5. Vane J. R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971 231 25 232 235 2-s2.0-0015237292
6. DuBois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., van de Putte L. B. A., Lipsky P. E., Cyclooxygenase in biology and disease. The FASEB Journal 1998 12 12 1063 1073 2-s2.0-0031689543 (Pubitemid 28418937)
7. Vane J. R., Bakhle Y. S., Botting R. M., Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998 38 97 120 2-s2.0-0031777185 (Pubitemid 28231490)
8. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C., Kvien T. K., Schnitzer T. J., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine 2000 343 21 1520 1528 2-s2.0-0034707105 10.1056/NEJM200011233432103
9. Bresalier R. S., Sandler R. S., Quan H., Bolognese J. A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M. A., Baron J. A., Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine 2005 352 11 1092 1102 2-s2.0-19744380776 10.1056/NEJMoa050493 (Pubitemid 40365350)
10. Rigas B., Kashfi K., Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends in Molecular Medicine 2004 10 7 324 330 2-s2.0-3042837373 10.1016/j.molmed.2004.05.004 (Pubitemid 38881521)
11. Krieger J. N., Nyberg L. Jr., Nickel J. C., NIH consensus definition and classification of prostatitis. The Journal of the American Medical Association 1999 282 3 236 237 2-s2.0-0033591899 10.1001/jama.282.3.236 (Pubitemid 29343164)
12. Canale D., Scaricabarozzi I., Giorgi P., Turchi P., Ducci M., Menchini-Fabris G. F., Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis. Andrologia 1993 25 3 163 166 2-s2.0-0027212996 (Pubitemid 23140119)
13. Nickel J. C., Pontari M., Moon T., Gittelman M., Malek G., Farrington J., Pearson J., Krupa D., Bach M., Drisko J., A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. The Journal of Urology 2003 169 4 1401 1405 2-s2.0-0037376299 10.1097/01.ju.0000054983.45096.16 (Pubitemid 36323796)
14. Parsons J. K., Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Current Bladder Dysfunction Reports 2010 5 4 212 218 2-s2.0-77956261394 10.1007/s11884-010-0067-2
15. Nickel J. C., Inflammation and benign prostatic hyperplasia. Urologic Clinics of North America 2008 35 1 109 115 2-s2.0-36448975493 10.1016/j.ucl.2007.09.012 (Pubitemid 350166524)
16. Chughtai B., Lee R., Te A., Kaplan S., Role of inflammation in benign prostatic hyperplasia. Reviews in Urology 2011 13 3 147 150
17. Kohnen P. W., Drach G. W., Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. The Journal of Urology 1979 121 6 755 760 2-s2.0-0018765076 (Pubitemid 9205780)
18. di Silverio F., Gentile V., de Matteis A., Mariotti G., Giuseppe V., Luigi P. A., Sciarra A., Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. European Urology 2003 43 2 164 175 2-s2.0-0037326098 10.1016/S0302-2838(02)00548-1 (Pubitemid 36221971)
19. Steiner G. E., Newman M. E., Paikl D., Stix U., Memaran-Dagda N., Lee C., Marberger M. J., Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. The Prostate 2003 56 3 171 182 2-s2.0-0041669594 10.1002/pros.10238 (Pubitemid 36918167)
20. O'Neill G. P., Ford-Hutchinson A. W., Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letters 1993 330 2 156 160 2-s2.0-0027293391 (Pubitemid 23265121)
21. Kirschenbaum A., Klausner A. P., Lee R., Unger P., Yao S., Liu X.-H., Levine A. C., Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000 56 4 671 676 2-s2.0-0033829160 10.1016/S0090-4295(00) 00674-9
22. Lee L.-M., Pan C.-C., Cheng C.-J., Chi C.-W., Liu T.-Y., Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Research 2001 21 2 1291 1294 2-s2.0-0035011423 (Pubitemid 32494135)
23. Wang W., Bergh A., Damber J.-E., Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. The Prostate 2004 61 1 60 72 2-s2.0-4143109119 10.1002/pros.20061 (Pubitemid 39095695)
24. di Silverio F., Bosman C., Salvatori M., Albanesi L., Pannunzi L. P., Ciccariello M., Cardi A., Salvatori G., Sciarra A., Combination therapy with rofecoxib and finasteride in the treatment of men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). European Urology 2005 47 1 72 79 2-s2.0-9644272488 10.1016/j.eururo.2004.08.024 (Pubitemid 39575721)
25. Ozdemir I., Bozkurt O., Demir O., Aslan G., Esen A. A., Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009 74 2 431 435 2-s2.0-67651102648 10.1016/j.urology.2009. 01.088
26. Jhang J.-F., Jiang Y.-H., Kuo H.-C., Adding cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. International Journal of Clinical Practice 2013 67 12 1327 1333 10.1111/ijcp.12220
27. Kaye M., Aging, circadian weight change, and nocturia. Nephron Physiology 2008 109 1 p11 p18 2-s2.0-46349101156 10.1159/000129653 (Pubitemid 351919492)
28. St. Sauver J. L., Jacobson D. J., Mcgree M. E., Lieber M. M., Jacobsen S. J., Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. American Journal of Epidemiology 2006 164 8 760 768 2-s2.0-33749460341 10.1093/aje/kwj258 (Pubitemid 44522080)
29. Falahatkar S., Mokhtari G., Pourreza F., Asgari S. A., Kamran A. N., Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008 72 4 813 816 2-s2.0-52949131327 10.1016/j.urology.2008.04.069
30. Kahokehr A., Vather R., Nixon A., Hill A. G., Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU International 2013 111 2 304 311 10.1111/j.1464-410X.2012.11559.x
31. Schenk J. M., Calip G. S., Tangen C. M., Goodman P., Parsons J. K., Thompson I. M., Kristal A. R., Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology 2012 176 2 156 163 10.1093/aje/kwr524
32. Meigs J. B., Mohr B., Barry M. J., Collins M. M., McKinlay J. B., Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology 2001 54 9 935 944 2-s2.0-0034883143 10.1016/S0895-4356(01)00351-1 (Pubitemid 32771319)
33. Kang D., Andriole G. L., van de Vooren R. C., Crawford D., Chia D., Urban D. A., Reding D., Huang W.-Y., Hayes R. B., Risk behaviours and benign prostatic hyperplasia. BJU International 2004 93 9 1241 1245 2-s2.0-2942746644 10.1111/j.1464-410X.2004.04839.x (Pubitemid 38823945)
34. Verhamme K. M. C., Dieleman J. P., van Wijk M. A. M., van der Lei J., Bosch J. L. H. R., Stricker B. H. C., Sturkenboom M. C. J. M., Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Archives of Internal Medicine 2005 165 13 1547 1551 2-s2.0-23044451172 10.1001/archinte.165.13.1547 (Pubitemid 41058037)
35. Minnery C. H., Getzenberg R. H., Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen. The Journal of Urology 2005 174 1 375 379 2-s2.0-20444445530 10.1097/01.ju.0000161598.24740.34 (Pubitemid 40825761)
36. Altavilla D., Minutoli L., Polito F., Irrera N., Arena S., Magno C., Rinaldi M., Burnett B. P., Squadrito F., Bitto A., Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. British Journal of Pharmacology 2012 167 1 95 108 10.1111/j.1476-5381.2012. 01969.x
37. Kashiwagi E., Shiota M., Yokomizo A., Itsumi M., Inokuchi J., Uchiumi T., Naito S., Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Endocrine-Related Cancer 2013 20 3 431 441 10.1530/ERC-12-0344
38. de Marzo A. M., Platz E. A., Sutcliffe S., Xu J., Grönberg H., Drake C. G., Nakai Y., Isaacs W. B., Nelson W. G., Inflammation in prostate carcinogenesis. Nature Reviews Cancer 2007 7 4 256 269 2-s2.0-33947687854 10.1038/nrc2090 (Pubitemid 46486616)
39. Sfanos K. S., de Marzo A. M., Prostate cancer and inflammation: the evidence. Histopathology 2012 60 1 199 215 2-s2.0-84255204457 10.1111/j.1365-2559.2011.04033.x
40. Haverkamp J., Charbonneau B., Ratliff T. L., Prostate inflammation and its potential impact on prostate cancer: a current review. Journal of Cellular Biochemistry 2008 103 5 1344 1353 2-s2.0-41749083284 10.1002/jcb.21536 (Pubitemid 351490705)
41. Gupta S., Srivastava M., Ahmad N., Bostwick D. G., Mukhtar H., Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate 2000 42 1 73 78 (Pubitemid 30004877)
42. Majima M., Amano H., Hayashi I., Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends in Pharmacological Sciences 2003 24 10 524 529 2-s2.0-0141918838 10.1016/j.tips.2003.08.005 (Pubitemid 37244005)
43. Veitonmäki T., Tammela T. L., Auvinen A., Murtola T. J., Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer 2013 49 4 938 945 10.1016/j.ejca.2012.09.030
44. Patel M. I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R. A., Cordon-Cardo C., Thaler H. T., Dannenberg A. J., Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical Cancer Research 2005 11 5 1999 2007 2-s2.0-16344389993 10.1158/1078-0432.CCR-04- 1877 (Pubitemid 40471866)
45. Hsu A.-L., Ching T.-T., Wang D.-S., Song X., Rangnekar V. M., Chen C.-S., The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. The Journal of Biological Chemistry 2000 275 15 11397 11403 2-s2.0-0034646688 10.1074/jbc.275.15.11397 (Pubitemid 30212792)
46. Kulp S. K., Yang Y.-T., Hung C.-C., Chen K.-F., Lai J.-P., Tseng P.-H., Fowble J. W., Ward P. J., Chen C.-S., 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Research 2004 64 4 1444 1451 2-s2.0-1242271208 10.1158/0008-5472.CAN-03-2396 (Pubitemid 38235615)
47. Inoue T., Anai S., Onishi S., Miyake M., Tanaka N., Hirayama A., Fujimoto K., Hirao Y., Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urology 2013 13, article 1 10.1186/1471-2490-13-1
48. Zheng X., Cui X.-X., Gao Z., Zhao Y., Lin Y., Shih W. J., Huang M.-T., Liu Y., Rabson A., Reddy B., Yang C. S., Conney A. H., Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prevention Research 2010 3 1 114 124 2-s2.0-77649195951 10.1158/1940-6207.CAPR-09-0059
49. Abedinpour P., Baron V. T., Welsh J., Borgström P., Regression of prostatetumors upon combination of hormone ablation therapy and celecoxib in vivo. The Prostate 2011 71 8 813 823 2-s2.0-79953676015 10.1002/pros.21297
50. Narayanan B. A., Narayanan N. K., Pittman B., Reddy B. S., Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clinical Cancer Research 2004 10 22 7727 7737 2-s2.0-9344225155 10.1158/1078-0432.CCR-04-0732 (Pubitemid 39557538)
51. Gupta S., Adhami V. M., Subbarayan M., MacLennan G. T., Lewin J. S., Hafeli U. O., Fu P., Mukhtar H., Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 2004 64 9 3334 3343 2-s2.0-2342625403 10.1158/0008-5472.CAN-03-2422 (Pubitemid 38581441)
52. Narayanan B. A., Narayanan N. K., Pttman B., Reddy B. S., Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. The Prostate 2006 66 3 257 265 2-s2.0-31944447030 10.1002/pros.20331 (Pubitemid 43191225)
53. Narayanan B. A., Condon M. S., Bosland M. C., Narayanan N. K., Reddy B. S., Suppression of N -methyl- N -nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clinical Cancer Research 2003 9 9 3503 3513 2-s2.0-0041833663 (Pubitemid 37082750)
54. Royle J. S., Ross J. A., Ansell I., Bollina P., Tulloch D. N., Habib F. K., Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. The Journal of Urology 2004 172 1 338 344 2-s2.0-3242778622
55. Huguenin S., Fleury-Feith J., Kheuang L., Jaurand M.-C., Bolla M., Riffaud J.-P., Chopin D. K., Vacherot F., Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. The Prostate 2004 61 2 132 141 2-s2.0-4544293476 10.1002/pros.20081 (Pubitemid 39244700)
56. Stewart G. D., Nanda J., Brown D. J. G., Riddick A. C. P., Ross J. A., Habib F. K., NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International Journal of Cancer 2009 124 1 223 232 2-s2.0-58149388709 10.1002/ijc.23934
57. Lu W., Tinsley H. N., Keeton A., Qu Z., Piazza G. A., Li Y., Suppression of Wnt/ β -catenin signaling inhibits prostate cancer cell proliferation. European Journal of Pharmacology 2009 602 1 8 14 2-s2.0-57249108188 10.1016/j.ejphar.2008.10.053
58. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
59. Nelson J. E., Harris R. E., Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncology Reports 2000 7 1 169 170 2-s2.0-0033631452
60. Habel L. A., Zhao W., Stanford J. L., Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes & Control 2002 13 5 427 434 2-s2.0-0035987765 10.1023/A:1015788502099 (Pubitemid 34666598)
61. Smith M. R., Manola J., Kaufman D. S., Oh W. K., Bubley G. J., Kantoff P. W., Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Journal of Clinical Oncology 2006 24 18 2723 2728 2-s2.0-33745563531 10.1200/JCO.2005.03.7804 (Pubitemid 46630568)
62. Norrish A. E., Jackson R. T., McRae C. U., Non-steroidal anti-inflammatory drugs and prostate cancer progression. International Journal of Cancer 1998 77 4 511 515 (Pubitemid 28340895)
63. Salinas C. A., Kwon E. M., Fitzgerald L. M., Feng Z., Nelson P. S., Ostrander E. A., Peters U., Stanford J. L., Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. American Journal of Epidemiology 2010 172 5 578 590 2-s2.0-77956240092 10.1093/aje/kwq175
64. Roberts R. O., Jacobson D. J., Girman C. J., Rhodes T., Lieber M. M., Jacobsen S. J., A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proceedings 2002 77 3 219 225 2-s2.0-0036183346 (Pubitemid 34177596)
65. Pruthi R. S., Derksen J. E., Moore D., A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU International 2004 93 3 275 278 2-s2.0-1342310048 10.1111/j.1464-410X.2004.04601.x (Pubitemid 38253569)
66. Menezes R. J., Swede H., Niles R., Moysich K. B., Regular use of aspirin and prostate cancer risk (United States). Cancer Causes & Control 2006 17 3 251 256 2-s2.0-32944459557 10.1007/s10552-005-0450-z (Pubitemid 43261888)
67. Bosetti C., Talamini R., Negri E., Franceschi S., Montella M., la Vecchia C., Aspirin and the risk of prostate cancer. European Journal of Cancer Prevention 2006 15 1 43 45 2-s2.0-30044439706 10.1097/01.cej.0000180665.04335.de (Pubitemid 43048741)
68. Langman M. J. S., Cheng K. K., Gilman E. A., Lancashire R. J., Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. British Medical Journal 2000 320 7250 1642 1646 2-s2.0-0034679222 (Pubitemid 30364636)
69. Leitzmann M. F., Stampfer M. J., Ma J., Chan J. M., Colditz G. A., Willett W. C., Giovannucci E., Aspirin use in relation to risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention 2002 11 10 1108 1111 2-s2.0-0036801502 (Pubitemid 35192666)